Abstract
Background: Multiple sclerosis (MS) is one of the most widespread chronic neurological diseases that manifests itself by progressive demyelination in the central nervous system. The study of MS pathogenesis begins with the onset of the relapsing–remitting phase of the disease, which becomes apparent due to microglia activation, neuroinflammation and demyelination/ remyelination in the white matter. The following progressive phase is accompanied by severe neurological symptoms when demyelination and neurodegeneration are spread to both gray and white matter. In this review, we discuss a possible role of mitochondrial reactive oxygen species (mtROS) in MS pathogenesis, mechanisms of mtROS generation and effects of some mitochondria-targeted antioxidants as potential components of MS therapy.
Results: In the early phase of MS, mtROS stimulate NLRP3 inflammasomes, which is critical for the formation of local inflammatory lesions. Later, mtROS contribute to blood-brain barrier disruption induced by mediators of inflammation, followed by infiltration of leukocytes. ROS generated by leukocytes and activated microglia promote mitochondrial dysfunction and oligodendrocyte cell death. In the progressive phase, neurodegeneration also depends on excessive mtROS generation. Currently, only a few immunomodulatory drugs are approved for treatment of MS. These drugs mainly reduce the number of relapses but do not stop MS progression. Certain dietary and synthetic antioxidants have demonstrated encouraging results in animal models of MS but were ineffective in the completed clinical trials. Conclusion: Novel mitochondria-targeted antioxidants could be promising components of combined programs for MS therapy considering that they can be applied at extremely low doses and concurrently demonstrate anti-inflammatory and neuroprotective activities.Keywords: Multiple sclerosis, oligodendrocytes, demyelination, inflammasome, mitochondria, reactive oxygen species, mitochondria-targeted antioxidants, neuroprotection.
Current Medicinal Chemistry
Title:Mitochondria-targeted Antioxidants as a Prospective Therapeutic Strategy for Multiple Sclerosis
Volume: 24 Issue: 19
Author(s): Elena Fetisova, Boris Chernyak*, Galina Korshunova, Maria Muntyan*Vladimir Skulachev
Affiliation:
- Belozersky Institute of Physico-Chemical Biology, Lomonosov Moscow State University, 119991 Moscow,Russian Federation
- Belozersky Institute of Physico-Chemical Biology, Lomonosov Moscow State University, 119991 Moscow,Russian Federation
Keywords: Multiple sclerosis, oligodendrocytes, demyelination, inflammasome, mitochondria, reactive oxygen species, mitochondria-targeted antioxidants, neuroprotection.
Abstract: Background: Multiple sclerosis (MS) is one of the most widespread chronic neurological diseases that manifests itself by progressive demyelination in the central nervous system. The study of MS pathogenesis begins with the onset of the relapsing–remitting phase of the disease, which becomes apparent due to microglia activation, neuroinflammation and demyelination/ remyelination in the white matter. The following progressive phase is accompanied by severe neurological symptoms when demyelination and neurodegeneration are spread to both gray and white matter. In this review, we discuss a possible role of mitochondrial reactive oxygen species (mtROS) in MS pathogenesis, mechanisms of mtROS generation and effects of some mitochondria-targeted antioxidants as potential components of MS therapy.
Results: In the early phase of MS, mtROS stimulate NLRP3 inflammasomes, which is critical for the formation of local inflammatory lesions. Later, mtROS contribute to blood-brain barrier disruption induced by mediators of inflammation, followed by infiltration of leukocytes. ROS generated by leukocytes and activated microglia promote mitochondrial dysfunction and oligodendrocyte cell death. In the progressive phase, neurodegeneration also depends on excessive mtROS generation. Currently, only a few immunomodulatory drugs are approved for treatment of MS. These drugs mainly reduce the number of relapses but do not stop MS progression. Certain dietary and synthetic antioxidants have demonstrated encouraging results in animal models of MS but were ineffective in the completed clinical trials. Conclusion: Novel mitochondria-targeted antioxidants could be promising components of combined programs for MS therapy considering that they can be applied at extremely low doses and concurrently demonstrate anti-inflammatory and neuroprotective activities.Export Options
About this article
Cite this article as:
Fetisova Elena, Chernyak Boris *, Korshunova Galina , Muntyan Maria*, Skulachev Vladimir, Mitochondria-targeted Antioxidants as a Prospective Therapeutic Strategy for Multiple Sclerosis, Current Medicinal Chemistry 2017; 24 (19) . https://dx.doi.org/10.2174/0929867324666170316114452
| DOI https://dx.doi.org/10.2174/0929867324666170316114452 |
Print ISSN 0929-8673 |
| Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the Treatment of Chronic Inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Evolving Insights into the Pathophysiology of Diabetic Neuropathy: Implications of Malfunctioning Glia and Discovery of Novel Therapeutic Targets
Current Pharmaceutical Design Non-dipping Status in Arterial Hypertension: An Overview
Current Vascular Pharmacology Binding of the PET Radiotracer [<sup>18</sup>F]BF227 Does not Reflect the Presence of Alpha-Synuclein Aggregates in Transgenic Mice
Current Alzheimer Research The Effect of Proton Pump Inhibitors on the Human Microbiota
Current Drug Metabolism Transplantation of Stem Cells as a Potential Therapeutic Strategy in Neurodegenerative Disorders
Current Stem Cell Research & Therapy Application of NMR Spectroscopy in Medicinal Chemistry and Drug Discovery
Current Topics in Medicinal Chemistry Role of Estrogen Receptors and GPR30/GPER in Glucose Homeostasis
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) The Aging of the Adaptive Immune System
Current Immunology Reviews (Discontinued) Activity of Drugs and Components of Natural Origin in the Severe Myoclonic Epilepsy of Infancy (Dravet Syndrome)
Central Nervous System Agents in Medicinal Chemistry Biological Strategies to Enhance Rotator Cuff Healing.
Current Stem Cell Research & Therapy Recent Advances in Progressive Supranuclear Palsy: A Review
Current Alzheimer Research Is Tretinoin Still a Key Agent for Photoaging Management?
Mini-Reviews in Medicinal Chemistry Recent Progress of Imaging Agents for Parkinson’s Disease
Current Neuropharmacology RNA-based Therapeutics: Master Regulator for Bioengineering Systems in Medicine World
Current Biotechnology Cholinesterase Inhibitors Modulate Autonomic Function in Patients with Alzheimer´s Disease and Mixed Dementia
Current Alzheimer Research Association Between Atrophy of the Caudate Nuclei, Global Brain Atrophy, Cerebral Small Vessel Disease and Mild Parkinsonian Signs in Neurologically and Cognitively Healthy Subjects Aged 45-84 Years: A Crosssectional Study
Current Alzheimer Research Protein Conformational Misfolding and Amyloid Formation: Characteristics of a New Class of Disorders that Include Alzheimers and Prion Diseases
Current Medicinal Chemistry Investigating Drug-induced Mitochondrial Toxicity: A Biosensor to Increase Drug Safety?
Current Drug Safety Renovascular Hypertension: Lesion Detection, Patient Selection, Treatment Options and Results
Current Hypertension Reviews Topical Antimicrobials for Burn Wound Infections
Recent Patents on Anti-Infective Drug Discovery





